Skip Nav Destination
Issues
15 January 2008
-
Cover Image
Cover Image
An enzyme/prodrug strategy incorporating multi-modal real-time imaging of prodrug enzyme delivery and clearance was designed to optimally time prodrug administration and limit systemic drug toxicity. Tracking fluorescently labeled bacterial cytosine deaminase (red) uptake by liver Kupffer cells (green), where co-localization is in yellow, exemplifies one imaging modality of this multimodal imaging approach. For further details, please see Li and colleagues on page 515 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Molecular Pathways
Report from the FDA
Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
Michael Brave; Vicki Goodman; Edvardas Kaminskas; Ann Farrell; William Timmer; Sarah Pope; Ravi Harapanhalli; Haleh Saber; David Morse; Julie Bullock; Angela Men; Carol Noory; Roshni Ramchandani; Leslie Kenna; Brian Booth; Joga Gobburu; Xiaoping Jiang; Rajeshwari Sridhara; Robert Justice; Richard Pazdur
Review
Human Cancer Biology
Large Deletions of the PRKAR1A Gene in Carney Complex
Anelia Horvath; Ioannis Bossis; Christoforos Giatzakis; Elizabeth Levine; Frank Weinberg; Elise Meoli; Audrey Robinson-White; Jennifer Siegel; Payal Soni; Lionel Groussin; Ludmila Matyakhina; Somya Verma; Elaine Remmers; Maria Nesterova; J. Aidan Carney; Jérôme Bertherat; Constantine A. Stratakis
Imaging, Diagnosis, Prognosis
Clinical Validation of a Customized Multiple Signature Microarray for Breast Cancer
Benita K.T. Tan; Lay Keng Tan; Kun Yu; Puay Hoon Tan; Ming Lee; Lang Hiong Sii; Chow Yin Wong; Gay Hui Ho; Allen W.Y. Yeo; Pierce K.H. Chow; Heng Nung Koong; Wei Sean Yong; Dennis T.H. Lim; London L.P.J. Ooi; Khee Chee Soo; Patrick Tan
Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples
Koji Yoshimoto; Julie Dang; Shaojun Zhu; David Nathanson; Tiffany Huang; Rebecca Dumont; David B. Seligson; William H. Yong; Zhenggang Xiong; Nagesh Rao; Henrik Winther; Arnab Chakravarti; Darell D. Bigner; Ingo K. Mellinghoff; Steve Horvath; Webster K. Cavenee; Timothy F. Cloughesy; Paul S. Mischel
Cancer Therapy: Clinical
Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Razelle Kurzrock; Hagop M. Kantarjian; Michelle A. Blascovich; Cindy Bucher; Srdan Verstovsek; John J. Wright; Susan R. Pilat; Jorge E. Cortes; Elihu H. Estey; Francis J. Giles; Miloslav Beran; Said M. Sebti
Cancer Therapy: Preclinical
A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Rosa Lapalombella; Xiaobin Zhao; Georgia Triantafillou; Bo Yu; Yan Jin; Gerard Lozanski; Carolyn Cheney; Nyla Heerema; David Jarjoura; Amy Lehman; L. James Lee; Guido Marcucci; Robert J. Lee; Michael A. Caligiuri; Natarajan Muthusamy; John C. Byrd
Cancer Susceptibility and Prevention
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds